van Leuven Sander I, Kastelein John J P, Hayden Michael R, d'Cruz David, Hughes Graham R, Stroes Erik S
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Curr Opin Lipidol. 2005 Oct;16(5):501-6. doi: 10.1097/01.mol.0000182533.19135.cb.
The recognition that inflammation is a hallmark of atherosclerotic disease has led to a series of studies reporting accelerated atherogenesis in chronic inflammatory diseases. Indeed, systemic lupus erythematosus is associated with an increased incidence of cardiovascular disease and the etiology thereof deserves closer attention.
The association between systemic lupus erythematosus and accelerated atherosclerosis has recently been confirmed by surrogate-marker studies for cardiovascular disease in patients with systemic lupus erythematosus. Since the propensity towards cardiovascular disease cannot solely be explained by classical risk factors, disease-specific pathways have been put forward as additional risk factors.
In the present review, we will discuss several of these factors as well as their potential impact for future prevention strategies in systemic lupus erythematosus.
认识到炎症是动脉粥样硬化疾病的一个标志,已引发了一系列研究,报告称慢性炎症性疾病中动脉粥样硬化进程加速。事实上,系统性红斑狼疮与心血管疾病发病率增加相关,其病因值得更密切关注。
系统性红斑狼疮与加速动脉粥样硬化之间的关联最近已通过系统性红斑狼疮患者心血管疾病的替代标志物研究得到证实。由于心血管疾病倾向不能仅由经典危险因素来解释,已提出疾病特异性途径作为额外的危险因素。
在本综述中,我们将讨论其中的几个因素及其对系统性红斑狼疮未来预防策略的潜在影响。